The Role of Hospital Pharmacists and Pharmaceutical-Care Interventions in the Personalized Management of Patients with Non-Small-Cell Lung Cancer: A Scoping Review

Background: Patients with non-small-cell lung cancer (NSCLC) increasingly receive oral targeted therapies and immune checkpoint inhibitors, creating complex medication-management and toxicity-monitoring needs. Pharmacists may contribute through medication optimization, adherence support, patient education, drug-interaction management and multidisciplinary toxicity prevention. Objectives: The objectives of this study were To systematically map the published evidence describing pharmacist and pharmaceutical-care roles relevant to medication safety, adherence, toxicity management, and treatment continuity in NSCLC. Methods: A scoping review was conducted using PubMed/MEDLINE and Web of Science, supplemented by citation and supplementary searching. The search was limited to English-language publications published between 28 August 2016 and 28 August 2026. After reconciliation, 481 unique records were screened. Eligibility was assessed against a NSCLC-specific population and pharmacy/pharmaceutical-care concept criteria. Evidence was classified as core/direct or contextual/supporting. The selection process was reported according to PRISMA-ScR. Results: Of 481 unique records screened, 444 were excluded at title/abstract screening and 37 reports underwent an eligibility assessment. Twenty-three were excluded at this stage, leaving 14 sources of evidence: 11 core/direct and three contextual/supporting sources. Core evidence covered medication optimization and drug–drug interactions, adherence monitoring, adverse-event/toxicity management, patient education, and pharmacist-led ambulatory or multidisciplinary services. Conclusions: Pharmacists contribute meaningfully to medication safety, adherence, toxicity management, and treatment continuity in NSCLC, but the evidence base remains heterogeneous. Larger prospective studies and economic evaluations are needed.

Authors

Publication Details

Journal
Pharmacy
Published
2026-11-19
DOI
https://doi.org/10.3390/pharmacy14080173
Primary Topic
Pharmacy and Medical Practices
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Role of Hospital Pharmacists and Pharmaceutical-Care Interventions in the Personalized Management of Patients with Non-Small-Cell Lung Cancer: A Scoping Review

Marina Yordanova, Tsvetomir Aleksandrov, Galina R. Petrova, Neli Nikolova
2 links
Pharmacy
Pharmacy and Medical Practices
article

The Role of Hospital Pharmacists and Pharmaceutical-Care Interventions in the Personalized Management of Patients with Non-Small-Cell Lung Cancer: A Scoping Review

Marina Yordanova, Tsvetomir Aleksandrov, Galina R. Petrova, Neli Nikolova
article en

Abstract

Background: Patients with non-small-cell lung cancer (NSCLC) increasingly receive oral targeted therapies and immune checkpoint inhibitors, creating complex medication-management and toxicity-monitoring needs. Pharmacists may contribute through medication optimization, adherence support, patient education, drug-interaction management and multidisciplinary toxicity prevention. Objectives: The objectives of this study were To systematically map the published evidence describing pharmacist and pharmaceutical-care roles relevant to medication safety, adherence, toxicity management, and treatment continuity in NSCLC. Methods: A scoping review was conducted using PubMed/MEDLINE and Web of Science, supplemented by citation and supplementary searching. The search was limited to English-language publications published between 28 August 2016 and 28 August 2026. After reconciliation, 481 unique records were screened. Eligibility was assessed against a NSCLC-specific population and pharmacy/pharmaceutical-care concept criteria. Evidence was classified as core/direct or contextual/supporting. The selection process was reported according to PRISMA-ScR. Results: Of 481 unique records screened, 444 were excluded at title/abstract screening and 37 reports underwent an eligibility assessment. Twenty-three were excluded at this stage, leaving 14 sources of evidence: 11 core/direct and three contextual/supporting sources. Core evidence covered medication optimization and drug–drug interactions, adherence monitoring, adverse-event/toxicity management, patient education, and pharmacist-led ambulatory or multidisciplinary services. Conclusions: Pharmacists contribute meaningfully to medication safety, adherence, toxicity management, and treatment continuity in NSCLC, but the evidence base remains heterogeneous. Larger prospective studies and economic evaluations are needed.

PharmacyVol. 14(8)
Good health and well-being
Pharmacy and Medical Practices
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon